Results 111 to 120 of about 35,754 (249)

The gut microbiome and drug‐resistant epilepsy: Microbiome–antiseizure medication interactions and implications for pharmacoresistance

open access: yesEpilepsia Open, EarlyView.
Abstract Drug‐resistant epilepsy (DRE) affects approximately one‐third of patients with epilepsy and represents a major unmet clinical need. While traditional hypotheses of pharmacoresistance have focused on alterations in drug targets, efflux transporter overexpression, and intrinsic disease severity, the gut microbiome has recently emerged as a ...
Khaled Zammar   +4 more
wiley   +1 more source

Valproic Acid

open access: yesNew England Journal of Medicine, 1980
openaire   +2 more sources

Somatic cell reprogramming for Parkinson's disease treatment

open access: yesIbrain, Volume 11, Issue 1, Page 59-73, Spring 2025.
The fundamental purpose of cell reprogramming to treat Parkinson's disease is to generate dopaminergic neurons (DAN) and do transplantation. There are two ways to accomplish this. One method is to induce cells into induced DA neurons (iDAN) directly or to induce cells into induced pluripotent stem cells and ultimately into iDAN in vitro. Another option
Xiaozhuo Li, Kevin Fang, Fengping Wang
wiley   +1 more source

Epigenetic Dysregulation of Somatostatin Receptors (SSTR) 1–5 and Therapeutic Implications in Neuroendocrine and Non‐Neuroendocrine Malignancies

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Somatostatin receptors (SSTR) mediate the antiproliferative, antisecretory, and proapoptotic effects of somatostatin and its synthetic analogs. Their surface expression on neuroendocrine tumor (NET) cells is required for somatostatin analog therapy and radiopharmaceutical therapy (RPT).
Neeraj Kumari   +10 more
wiley   +1 more source

Synthesis and Characterization of Juglone‐Derived cu (II), Mn (II) and Zn (II) Complexes and Investigation of Their Cytotoxic Activities Against Lung and Colon Cancer Cells in Vitro and in Silico

open access: yesJournal of Applied Toxicology, EarlyView.
ABSTRACT Three new Zn (II), Cu (II) and Mn (II) complexes have been synthesized from 5‐hydroxy‐1,4‐naphthoquinone (HNQ). Elemental analysis, magnetic susceptibility, UV–Vis, IR and Mass spectrometry have all been used to explore the structural characterization of these compounds.
Mustafa Öztatlıcı   +5 more
wiley   +1 more source

Hydroxamic Acids as HDAC Inhibitor Drug Leads for Malaria

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT Malaria is a global health threat, with an estimated 282 million cases and 610,000 malaria‐associated deaths reported in 2024. Most mortality is due to infection by Plasmodium falciparum parasites, with the highest burden occurring in Sub‐Saharan Africa.
Wisam A. Dawood   +7 more
wiley   +1 more source

Advancing Therapies for Mycobacterial Diseases: From Small Molecules to Host‐Directed Strategies

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT The global burden of multidrug‐resistant tuberculosis (MDR‐TB) and the rising incidence of nontuberculous mycobacterial (NTM) infections highlight the urgent need for innovative therapeutic strategies. Current treatments are prolonged, toxic, and increasingly compromised by resistance and limited diagnostic capacity.
Tânia Silva   +23 more
wiley   +1 more source

Polypharmacy among adolescents and adults with cerebral palsy in a clinical setting

open access: yesPM&R, EarlyView.
Abstract Background Adolescents and adults with cerebral palsy often experience multimorbidity related to their condition, which primarily affects movement and posture but is also associated with pain, epilepsy, mood disorders, and other conditions. As such, these patients are often prescribed a range of medications to manage symptoms, thereby putting ...
Caitlin Cassidy   +3 more
wiley   +1 more source

Beyond abstinence: Redefining success in cannabis use disorder treatment

open access: yesAddiction, EarlyView.
Abstract Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint.
Tobias B. Atkin   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy